Tatva Chintan Pharma Chem Ltd

- Tatva Chintan Pharma Chem Limited is in the process of raising funds amounting to Rs. 200 crore through a Qualified Institutions Placement (QIP), which involves issuing new shares, leading to capital infusion into the company. - The QIP will likely reduce promoter stake below 75%, aligning with SEBI guidelines. - The funds are intended for the next phase of expansion, including development on newly acquired land awaiting environmental clearance. - The company has already utilized approximately 97% of net proceeds from an earlier fundraising totaling Rs. 2072.81 million. - No specific mention of new debt fundraising was reported in the most recent call; however, interest costs remain high due to increased benchmark rates, with the last scheduled repayment of existing term loans in Q1 of next year.

- The company is raising approximately Rs. 200 crore through a Qualified Institutional Placement (QIP) to fund the next phase of expansion. - Proceeds will be used for the development of a new piece of land bought in 2021, which is on the verge of receiving environmental clearance (possibly by August or soon after). - The company expects to reach about 80-85% utilization of the newly expanded Dahej facility in the next financial year and is planning further expansion. - The Rs. 150 crore expanded Dahej plant's commercial production has commenced, with expectations for higher utilization from December 2023. - The capital expenditure will involve capacity enhancement particularly at Dahej and accelerating the launch of new products. - QIP issuance will dilute promoter stake below 75%, complying with SEBI guidelines. - Long-term focus on developing ultra-high purity products and entering new segments such as semiconductor materials and electrolyte salts for energy storage systems.

- Steady improvement expected over coming quarters with favorable product mix driving growth. - Revenue grew 29% YoY to ₹1,144 million in Q1 FY2024; EBITDA up 40% YoY, indicating strong profitability. - New product commercialization, especially in pharma and agro intermediates, expected to start contributing from Q4 FY2024 and early 2025. - Energy storage/electrolyte salts segment to see strong growth with four customers engaged; key turning point expected in calendar year 2025. - Flame retardants segment to stabilize with production starting September 2023; revenue guidance of ₹25-40 crore for current fiscal maintained. - Capacity utilization expected to ramp up to ~80-85% in expanded Dahej facility by next financial year supporting volume growth. - QIP funding to support next phase of expansion, target increasing capacity and product pipeline. - Anticipated gross margin normalization and better pricing to sustain profitability. - SDA segment demand expected to ramp up strongly by end 2023, aiding revenue growth.

- Gross margins expected to recover to around 55% by Q3 FY2024 as inventory clearance completes and product mix improves (Parth Mehta & Chintan Shah). - Utilization of the newly expanded Dahej facility expected to reach 80-85% by FY2025, enhancing cost absorption and margins. - EBITDA margins projected to improve with ramp-up in SDA demand, electrolyte salts, and flame retardant segments from Q4 FY2024. - Stabilization and slight recovery in pricing for key products after earlier price corrections, supporting margin improvement. - Depreciation expense increased due to recent capex, but no one-offs expected; steady quarterly depreciation going forward. - Revenue growth expected from increased commercial production, new product approvals, and entry into new markets. - QIP fund raise (~Rs.200 crore) intended to support next-phase expansions, indicating confidence in sustained growth. - Overall outlook: steady earnings growth and margin expansion from late FY2024 and into FY2025 as operations scale and pricing stabilizes.

- Two agrochemical products are currently on the production floor at a plant scale for customer validation, with commercial supplies expected to begin by late December 2023 or early January 2024. - Additionally, two pharmaceutical products are under validation and expected to commercialize in early 2025. - Out of these four products, two were mentioned in the previous quarter's order book; the other two are new additions. - The company is expanding its pipeline with products in the pilot stage aimed at commercialization. - For the electrolyte segment, the company is working towards pilot-scale delivery with expectations to start commercial activity by December 2023. - The order book is supported by steady demand and ongoing product qualification efforts, indicating a healthy outlook for future orders.